- UK firm Phytopharma's Zemaphyte has achieved "highly significant" reductions in symptoms in severely-affected atopic eczema patients, according to interim results of a Phase III trial. Zemaphyte, an extract of plants used in traditional Chinese medicine, reduced the number of lesions with no unexpected side effects. The firm says the study should be concluded later this year, and plans to file for approval in the UK shortly. Once approved, Zemaphyte will be marketed in Europe by Rhone-Poulenc Rorer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze